Shopping Cart 0
Cart Subtotal
USD 0

Orchard Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Orchard Therapeutics Ltd (Orchard) is an integrated commercial-stage biotechnology company that develops gene therapies for the treatment of serious and life-threatening orphan diseases. Its pipeline products include Strimvelis, an autologous ex vivo gammaretroviral gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID); OTL-103 for Wiskott-Aldrich syndrome (WAS); OTL-102 for X-linked chronic granulomatous disease (X-CGD); OTL-300 for transfusion-dependent beta-thalassemia; and OTL-200 for metachromatic leukodystrophy (MLD), among others. The company works in partnership with institutions that specialize in gene and cell therapy such as The University of Manchester, Boston Children's Hospital, and The San Raffaele Telethon Institute for Gene Therapy. It has operations in US and the UK with offices in London, San Francisco and Boston. Orchard is headquartered in London, the UK.

Orchard Therapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12

Venture Financing 13

Orchard Therapeutics Raises USD150 Million in Series C Financing 13

Orchard Therapeutics Raises USD110 Million in Series B Financing 16

Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18

Partnerships 19

Orchard Therapeutics and MolMed Expand Collaboration Agreement 19

Orchard Therapeutics Enters into Agreement with Genethon 20

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21

Licensing Agreements 23

Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23

Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24

Orchard Therapeutics Ltd-Key Competitors 25

Orchard Therapeutics Ltd-Key Employees 26

Orchard Therapeutics Ltd-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Aug 28, 2018: Orchard Therapeutics expands leadership team with appointments of head of corporate communications and head of human resources 28

Aug 02, 2018: Orchard Therapeutics appoints Jon Ellis to Board of Directors 29

Jul 09, 2018: Orchard Therapeutics Names Joanne Beck As Board Director 30

Jun 29, 2018: Orchard Therapeutics Appoints Jim Geraghty as Chairman of its Board of Directors 31

Jun 07, 2018: Orchard Therapeutics Appoints Marc Dunoyer And Charlie Rowland As Board Directors 32

Mar 21, 2018: Orchard Therapeutics Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer and General Counsel 33

Feb 21, 2018: Orchard Therapeutics Appoints Dr. Harry Malech to Scientific Advisory Board 34

Jan 17, 2018: Orchard Therapeutics Appoints Frank Thomas as Chief Financial Officer and Chief Business Officer 35

Aug 10, 2017: Orchard Therapeutics appoints Mark Rothera as CEO 36

Government and Public Interest 37

Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost USD 32 Million Boost from Stem Cell Agency 37

Product News 39

10/23/2017: NICE approves gene therapy for rare 'bubble baby syndrome' 39

01/03/2018: NICE final draft guidance recommends gene therapy for rare 'bubble baby syndrome' 40

Product Approvals 41

May 03, 2018: Orchard Therapeutics OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy 41

Jul 24, 2017: Orchard Therapeutics announces that OTL-101 has Received a Rare Paediatric Disease Designation 42

Other Significant Developments 43

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orchard Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12

Orchard Therapeutics Raises USD150 Million in Series C Financing 13

Orchard Therapeutics Raises USD110 Million in Series B Financing 16

Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18

Orchard Therapeutics and MolMed Expand Collaboration Agreement 19

Orchard Therapeutics Enters into Agreement with Genethon 20

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21

Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23

Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24

Orchard Therapeutics Ltd, Key Competitors 25

Orchard Therapeutics Ltd, Key Employees 26

Orchard Therapeutics Ltd, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Orchard Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.